Roberta A Diotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6153610/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein. Journal of Virology, 2008, 82, 1047-1052.	3.4	119
2	Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. Emerging Microbes and Infections, 2021, 10, 206-209.	6.5	74
3	Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. Journal of Immunology Research, 2019, 2019, 1-13.	2.2	72
4	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut, 2016, 65, 512-523.	12.1	67
5	Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes. PLoS ONE, 2009, 4, e8254.	2.5	64
6	Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection. Journal of Infectious Diseases, 2020, 222, 722-725.	4.0	61
7	Weak correlation between antibody titers and neutralizing activity in sera from SARS oVâ€2 infected subjects. Journal of Medical Virology, 2021, 93, 2160-2167.	5.0	52
8	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. PLoS Pathogens, 2021, 17, e1009878.	4.7	52
9	Unconventional CD147â€dependent platelet activation elicited by SARSâ€CoVâ€2 in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, 20, 434-448.	3.8	50
10	Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology, 2010, 399, 144-152.	2.4	40
11	Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmunity Reviews, 2008, 7, 468-472.	5.8	33
12	A Biologically-validated HCV E1E2 Heterodimer Structural Model. Scientific Reports, 2017, 7, 214.	3.3	32
13	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Research, 2012, 96, 82-89.	4.1	27
14	Neutralization Interfering Antibodies: A "Novel―Example of Humoral Immune Dysfunction Facilitating Viral Escape?. Viruses, 2012, 4, 1731-1752.	3.3	26
15	Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides. Clinical and Developmental Immunology. 2013. 2013. 1-12.	3.3	26
16	Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiologica, 2009, 32, 319-24.	0.1	22
17	Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. Journal of Virology, 2019, 93, .	3.4	21
18	A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiologica, 2012, 35, 289-94.	0.1	20

Roberta A Diotti

#	Article	IF	CITATIONS
19	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. Frontiers in Microbiology, 2020, 11, 1704.	3.5	18
20	JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	16
21	HCV Proteins and Immunoglobulin Variable Gene (IgV) Subfamilies in HCV-Induced Type II Mixed Cryoglobulinemia: A Concurrent Pathogenetic Role. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	15
22	New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiologica, 2012, 35, 387-97.	0.1	15
23	Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy. Antiviral Research, 2014, 108, 94-103.	4.1	13
24	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses, 2021, 13, 1514.	3.3	12
25	Next Generation Vaccines for Infectious Diseases. Journal of Immunology Research, 2019, 2019, 1-2.	2.2	11
26	Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. Antiviral Research, 2017, 143, 48-61.	4.1	9
27	Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein. New Microbiologica, 2012, 35, 475-9.	0.1	8
28	Autoimmune hepatitis and occult HCV infection: A prospective single-centre clinical study. Autoimmunity Reviews, 2017, 16, 323-325.	5.8	6
29	Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. Virology Journal, 2020, 17, 103.	3.4	4
30	Editorial: Immunotherapeutic and Immunoprophylactic Strategies for Infectious Diseases. Frontiers in Immunology, 2020, 11, 1670.	4.8	3
31	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. Viruses, 2016, 8, 128.	3.3	2
32	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. Viruses, 2022, 14, 1232.	3.3	2
33	New Insights for Immune-Based Diagnosis and Therapy for Infectious Diseases. Journal of Immunology Research, 2017, 2017, 1-2.	2.2	1
34	Conventional and nontraditional delivery methods and routes of vaccine administration. , 2022, , 329-355.		0
35	New Insights into Immune-Based Diagnosis, Therapy and Prophylaxis for Infectious Diseases 2020. Journal of Immunology Research, 2021, 2021, 1-2.	2.2	0